FDA expands use of first sickle cell disease gene therapy for children as young as 2 years

FDA expands use of first sickle cell disease gene therapy for children as young as 2 years. The U.S.

A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.

Trechos de apoio da pauta: The U.S. Food and Drug Administration has issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients ages 2 and older with either sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent β thalassemia (TDT).

• Ponto de atenção: expands.
• Ponto de atenção: first.
• Ponto de atenção: sickle.

Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.